Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117112 | 1.00 | MAPT (0.64) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL1532466 | 1.00 | MAPT (0.64) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL3626201 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL13746761 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL5879052 | 0.98 | MAPT (0.62) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL25275005 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL8036038 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL16213113 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL2222385 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 | |
| SCHEMBL1134744 | 0.98 | ACE2 (0.66) | MAPTACE2FFAR4FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4416250-B1 | POLYAMIDE FUEL ADDITIVES | CHEVRON USA INC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENTS GMBH (DE) | 2025-10-16 | — | — | US | claimed |
| EP-4583721-A1 | COMPOSITIONS AND METHODS FOR PRODUCING MEAT-LIKE AROMAS | Nourish Ingredients Pty Ltd (AU) | 2025-07-16 | — | — | EP | claimed |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2025-02-20 | — | — | US | claimed |
| US-20240400920-A1 | POLYAMIDE FUEL ADDITIVES | CHEVRON U.S.A. INC. | 2024-12-05 | — | — | US | claimed |
| CN-118813214-A | Preparation method of amphiphilic temporary plugging agent and preparation method of polymer modified calcium carbonate plugging material | 中石化石油工程技术服务股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240306688-A1 | METHOD OF MITIGATING OFF-ODORS | GIVAUDAN SA (CH) | 2024-09-19 | — | — | US | claimed |
| US-12070049-B2 | Method of using branched-chain fatty acids to substantially emulate ruminant sensory profiles in plant- and cell-based meat and dairy products | Black Sheep Foods Inc. (US) | 2024-08-27 | — | — | US | claimed |
| EP-4416250-A1 | POLYAMIDE FUEL ADDITIVES | Chevron U.S.A. Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| EP-4391827-A1 | METHOD OF MITIGATING OFF-ODORS | Givaudan SA (CH) | 2024-07-03 | — | — | EP | claimed |
| US-20150297753-A1 | COMPOSITIONS FOR DELIVERY OF ORAL COMFORT SENSATIONS | THE PROCTER & GAMBLE COMPANY | 2015-10-22 | — | — | US | claimed |
| WO-2015073649-A1 | COMPOSITIONS FOR DELIVERY OF ORAL COMFORT SENSATIONS | THE PROCTER & GAMBLE COMPANY (US) | 2015-05-21 | — | — | WO | claimed |
| EP-2737901-A1 | Therapeutic Use of Compounds | UCL Business PLC (GB) | 2014-06-04 | — | — | EP | claimed |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS PLC (GB) | 2013-11-14 | — | — | US | claimed |
| EP-2642990-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL Business Plc. (GB) | 2013-10-02 | — | — | EP | claimed |
| WO-2012069790-A1 | THERAPEUTIC USE OF COMPOUNDS | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2012-05-31 | — | — | WO | claimed |
| EP-1745791-A2 | Treating cartilage/bone conditions with water-soluble strontium salts | Osteologix A/S (DK) | 2007-01-24 | — | — | EP | claimed |
| EP-0715497-B1 | FLAVOURING COMPOSITION AND PROCESS | FIRMENICH & CIE (CH) | 2000-10-04 | — | — | EP | claimed |
| US-5695802-A | ADDING TO FLAVORING INGREDIENT DIGLYCERIDE FRACTION OF HYDROLYZATE OF ANIMAL OR VEGETABLE FAT | FIRMENICH SA (CH) | 1997-12-09 | — | — | US | claimed |
| EP-0280443-B1 | Improvements in or relating to repellent compositions | DALGETY LTD (GB) | 1994-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | SLC39A11, SLC39A3, SLC39A7 | MAPT 128/4885ACE2 2841/4885FFAR4 3848/4885 |
| US-20130303616-A1 | THERAPEUTIC USE OF COMPOUNDS | BACE1, CPT1A, BCL6 | MAPT 551/4885ACE2 2880/4885FFAR4 880/4885 |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | CYP11B1, SGMS1, PTGER1 | MAPT 4007/4885ACE2 1765/4885FFAR4 1133/4885 |
| US-20150297753-A1 | COMPOSITIONS FOR DELIVERY OF ORAL COMFORT SENSATIONS | TRPA1, TRPV1, TRPV2 | MAPT 1905/4885ACE2 3881/4885FFAR4 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.